{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:39:40Z","timestamp":1740166780690,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharmaceuticals Corporation (US)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["SpringerPlus"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40064-016-3404-x","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T14:36:35Z","timestamp":1475678195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis"],"prefix":"10.1186","volume":"5","author":[{"given":"S.","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. F.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"K.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"issue":"6","key":"3404_CR1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1590\/S0034-89102012000600003","volume":"46","author":"AM Almeida","year":"2012","unstructured":"Almeida AM, Silva AL, Brandao CM et al (2012) Cost-effectiveness of nucleoside\/nucleotide analogues in chronic hepatitis B. Rev Saude Publica 46(6):942\u2013949","journal-title":"Rev Saude Publica"},{"issue":"4","key":"3404_CR2","first-page":"209","volume":"6","author":"T Biazar","year":"2015","unstructured":"Biazar T, Yahyapour Y, Hasanjani Roushan MR et al (2015) Relationship between hepatitis B DNA viral load in the liver and its histology in patients with chronic hepatitis B. Casp J Intern Med 6(4):209\u2013212","journal-title":"Casp J Intern Med"},{"issue":"14","key":"3404_CR3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMp1410425","volume":"372","author":"D Blumenthal","year":"2015","unstructured":"Blumenthal D, Hsiao W (2015) Lessons from the East\u2013China\u2019s rapidly evolving health care system. N Engl J Med 372(14):1281\u20131285","journal-title":"N Engl J Med"},{"issue":"2","key":"3404_CR4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11901-010-0042-6","volume":"9","author":"TM Chan","year":"2010","unstructured":"Chan TM (2010) Hepatitis B and Renal Disease. Curr Hepat Rep 9(2):99\u2013105","journal-title":"Curr Hepat Rep"},{"issue":"Suppl 1","key":"3404_CR5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12072-009-9143-0","volume":"3","author":"TT Chang","year":"2009","unstructured":"Chang TT (2009) On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 3(Suppl 1):16\u201323","journal-title":"Hepatol Int"},{"issue":"4","key":"3404_CR6","first-page":"405","volume":"32","author":"Chinese Society of Hepatology and\u00a0Chinese Society of Infectious Diseases","year":"2011","unstructured":"Chinese Society of Hepatology and\u00a0Chinese Society of Infectious Diseases, Chinese Medical Association (2011) The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Liu Xing Bing Xue Za Zhi 32(4):405\u2013415","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"3404_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/596829","volume":"2015","author":"G Deray","year":"2015","unstructured":"Deray G, Buti M, Gane E et al (2015) Hepatitis B virus Infection and the Kidney: renal abnormalities in HBV Patients, antiviral drugs handling, and specific follow-up. Advances in Hepatology 2015:1\u201311","journal-title":"Advances in Hepatology"},{"issue":"1","key":"3404_CR8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0168-8278(11)60368-1","volume":"54","author":"K Deterding","year":"2011","unstructured":"Deterding K, Lampe N, Reijnders J et al (2011) 366 prevalence and severity of kidney dysfunction in patients with chronic hepatitis B in Europe: data from the European Virgil cohort. J Hepatol 54(1):147","journal-title":"J Hepatol"},{"issue":"12","key":"3404_CR9","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","volume":"66","author":"J Fung","year":"2011","unstructured":"Fung J, Lai CL, Seto WK, Yuen MF (2011) Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 66(12):2715\u20132725","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3404_CR10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","volume":"146","author":"EJ Gane","year":"2014","unstructured":"Gane EJ, Deray G, Liaw YF et al (2014) Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 146(1):138\u2013146","journal-title":"Gastroenterology"},{"issue":"3","key":"3404_CR11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.23044","volume":"50","author":"NB Ha","year":"2009","unstructured":"Ha NB, Ha NB, Garcia RT et al (2009) Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 50(3):727\u2013734","journal-title":"Hepatology"},{"issue":"6","key":"3404_CR12","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jval.2012.06.005","volume":"15","author":"J He","year":"2012","unstructured":"He J, Bowen JM, Xie F, Goeree R (2012) Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health 15(6):894\u2013906","journal-title":"Value Health"},{"issue":"2","key":"3404_CR13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","volume":"47","author":"J Hou","year":"2008","unstructured":"Hou J, Yin YK, Xu D et al (2008) Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1\u00a0year of a randomized, double-blind trial. Hepatology 47(2):447\u2013454","journal-title":"Hepatology"},{"issue":"2","key":"3404_CR14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jvh.12313","volume":"22","author":"JL Hou","year":"2015","unstructured":"Hou JL, Gao ZL, Xie Q et al (2015) Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48\u00a0weeks: a randomized controlled trial. J Viral Hepat 22(2):85\u201393","journal-title":"J Viral Hepat"},{"issue":"21","key":"3404_CR15","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","volume":"324","author":"KN Lai","year":"1991","unstructured":"Lai KN, Li PK, Lui SF et al (1991) Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324(21):1457\u20131463","journal-title":"N Engl J Med"},{"issue":"2","key":"3404_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2):97\u2013107","journal-title":"J Viral Hepat"},{"issue":"3","key":"3404_CR17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","volume":"11","author":"AR Levy","year":"2008","unstructured":"Levy AR, Kowdley KV, Iloeje U et al (2008) The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 11(3):527\u2013538","journal-title":"Value Health"},{"issue":"6","key":"3404_CR18","first-page":"826","volume":"32","author":"X Li","year":"2012","unstructured":"Li X, Zhong C, Yang S et al (2012) Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao 32(6):826\u2013829","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"3","key":"3404_CR19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","volume":"3","author":"YF Liaw","year":"2009","unstructured":"Liaw YF (2009) HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 3(3):425\u2013433","journal-title":"Hepatol Int"},{"issue":"2","key":"3404_CR20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N et al (2009) 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136(2):486\u2013495","journal-title":"Gastroenterology"},{"issue":"9","key":"3404_CR21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrneph.2013.146","volume":"9","author":"ZH Liu","year":"2013","unstructured":"Liu ZH (2013) Nephrology in china. Nat Rev Nephrol 9(9):523\u2013528","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl 1","key":"3404_CR22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2005-915644","volume":"25","author":"BJ McMahon","year":"2005","unstructured":"McMahon BJ (2005) Epidemiology and natural history of hepatitis B. Semin Liver Dis 25(Suppl 1):3\u20138","journal-title":"Semin Liver Dis"},{"key":"3404_CR44","unstructured":"National Health and Family Planning Commission of the People\u2019s Republic of China (2015) http:\/\/www.moh.gov.cn\/publicfiles\/business\/htmlfiles\/mohkjjys\/s3578\/201005\/47399.htm . Accessed 3 Oct 2016"},{"issue":"1","key":"3404_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1010539511413258","volume":"25","author":"CJ Ng","year":"2013","unstructured":"Ng CJ, Low WY, Wong LP, Sudin MR, Mohamed R (2013) Uncovering the experiences and needs of patients with chronic hepatitis B infection at diagnosis: a qualitative study. Asia Pac J Public Health 25(1):32\u201340","journal-title":"Asia Pac J Public Health"},{"issue":"2","key":"3404_CR24","doi-asserted-by":"crossref","first-page":"e54279","DOI":"10.1371\/journal.pone.0054279","volume":"8","author":"T Piratvisuth","year":"2013","unstructured":"Piratvisuth T, Komolmit P, Tanwandee T et al (2013) 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS ONE 8(2):e54279","journal-title":"PLoS ONE"},{"issue":"1","key":"3404_CR25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.12229","volume":"22","author":"X Qi","year":"2015","unstructured":"Qi X, Wang JY, Mao RC, Zhang JM (2015) Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China. J Viral Hepat 22(1):46\u201354","journal-title":"J Viral Hepat"},{"issue":"2","key":"3404_CR26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4254\/wjh.v3.i2.31","volume":"3","author":"MC Robotin","year":"2011","unstructured":"Robotin MC (2011) Hepatitis B prevention and control: lessons from the East and the West. World J Hepatol 3(2):31\u201337","journal-title":"World J Hepatol"},{"issue":"1","key":"3404_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK et al (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10(1):1\u201398","journal-title":"Hepatol Int"},{"key":"3404_CR28","doi-asserted-by":"crossref","unstructured":"Shepherd J, Jones J, Takeda A, Davidson P, Price A (2006) Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 10(28):iii\u2013iv, xi\u2013xiv, 1\u2013183","DOI":"10.3310\/hta10280"},{"issue":"11","key":"3404_CR29","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/00019053-200826110-00006","volume":"26","author":"DE Spackman","year":"2008","unstructured":"Spackman DE, Veenstra DL (2008) A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 26(11):937\u2013949","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"3404_CR30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/hep.26885","volume":"59","author":"J Sun","year":"2014","unstructured":"Sun J, Xie Q, Tan D et al (2014) The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 59(4):1283\u20131292","journal-title":"Hepatology"},{"issue":"7","key":"3404_CR31","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/ndt\/gfr168","volume":"26","author":"J Tattersall","year":"2011","unstructured":"Tattersall J, Dekker F, Heimburger O et al (2011) When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant 26(7):2082\u20132086","journal-title":"Nephrol Dial Transplant"},{"key":"3404_CR32","doi-asserted-by":"crossref","unstructured":"Tsai MC, Chen CH, Tseng PL et al (2016) Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect 22(1): 95.e91-97","DOI":"10.1016\/j.cmi.2015.05.035"},{"issue":"1","key":"3404_CR33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1473-3099(15)00245-5","volume":"16","author":"C Vellozzi","year":"2016","unstructured":"Vellozzi C, Averhoff F (2016) An opportunity for further control of hepatitis B in China? Lancet Infect Dis 16(1):10\u201311","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"3404_CR34","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/jvh.12025","volume":"20","author":"Y Wang","year":"2013","unstructured":"Wang Y, Thongsawat S, Gane EJ et al (2013) Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 20(4):e37\u2013e46","journal-title":"J Viral Hepat"},{"issue":"12","key":"3404_CR35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jvh.12341","volume":"21","author":"GL Wong","year":"2014","unstructured":"Wong GL, Wong VW, Chan HL (2014) Combination therapy of interferon and nucleotide\/nucleoside analogues for chronic hepatitis B. J Viral Hepat 21(12):825\u2013834","journal-title":"J Viral Hepat"},{"key":"3404_CR45","unstructured":"Woodhead M (2015) How much does it cost to go to the doctor in China? http:\/\/www.chinesemedicalnews.com\/2015\/04\/how-much-does-it-cost-to-go-to-doctor.html . Accessed 3 Oct 2016"},{"key":"3404_CR46","unstructured":"World Bank National Accounts Data (2015) World Bank GDP per capita. http:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=CN . Accessed 3 Oct 2016"},{"key":"3404_CR47","unstructured":"World Health Organization (2012) Global health observatory data repository. http:\/\/apps.who.int\/gho\/data\/?theme=main&vid=60340 . Accessed 3 Oct 2016"},{"key":"3404_CR48","unstructured":"World Health Organization (2015) Hepatitis B. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ . Accessed 3 Oct 2016"},{"issue":"5","key":"3404_CR36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1524-4733.2010.00733.x","volume":"13","author":"B Wu","year":"2010","unstructured":"Wu B, Li T, Chen H, Shen J (2010) Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 13(5):592\u2013600","journal-title":"Value Health"},{"issue":"1","key":"3404_CR37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/1472-6963-12-385","volume":"12","author":"B Wu","year":"2012","unstructured":"Wu B, Shen J, Cheng H (2012) Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. BMC Health Serv Res 12(1):385","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"3404_CR38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11684-014-0331-5","volume":"8","author":"R Yu","year":"2014","unstructured":"Yu R, Fan R, Hou J (2014) Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med 8(2):135\u2013144","journal-title":"Front Med"},{"issue":"7","key":"3404_CR39","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","volume":"106","author":"MF Yuen","year":"2011","unstructured":"Yuen MF, Seto WK, Fung J et al (2011) Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 106(7):1264\u20131271","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3404_CR40","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MCG.0000000000000478","volume":"50","author":"MF Yuen","year":"2016","unstructured":"Yuen MF, Ahn SH, Chen DS et al (2016) Chronic hepatitis B virus infection: disease revisit and management recommendations. J Clin Gastroenterol 50(4):286\u2013294","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3404_CR41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","volume":"51","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem S, Gane E, Liaw YF et al (2009) Baseline characteristics and early on-treatment response predict the outcomes of 2\u00a0years of telbivudine treatment of chronic hepatitis B. J Hepatol 51(1):11\u201320","journal-title":"J Hepatol"},{"issue":"3","key":"3404_CR42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40261-015-0273-y","volume":"35","author":"C Zhang","year":"2015","unstructured":"Zhang C, Ke W, Gao Y et al (2015) Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. Clin Drug Investig 35(3):197\u2013209","journal-title":"Clin Drug Investig"},{"issue":"2","key":"3404_CR43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12659\/AOT.883217","volume":"17","author":"W Zhao","year":"2012","unstructured":"Zhao W, Zhang L, Han S et al (2012) Cost analysis of living donor kidney transplantation in China: a single-center experience. Ann Transplant 17(2):5\u201310","journal-title":"Ann Transplant"}],"container-title":["SpringerPlus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40064-016-3404-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40064-016-3404-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40064-016-3404-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T06:45:39Z","timestamp":1589697939000},"score":1,"resource":{"primary":{"URL":"http:\/\/springerplus.springeropen.com\/articles\/10.1186\/s40064-016-3404-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["3404"],"URL":"https:\/\/doi.org\/10.1186\/s40064-016-3404-x","relation":{},"ISSN":["2193-1801"],"issn-type":[{"type":"electronic","value":"2193-1801"}],"subject":[],"published":{"date-parts":[[2016,10,5]]},"article-number":"1719"}}